Breaking News Instant updates and real-time market news.

SFM

Sprouts Farmers Market

$22.02

1.14 (5.46%)

, WFM

Whole Foods

$29.53

0.06 (0.20%)

09:18
03/20/17
03/20
09:18
03/20/17
09:18

On The Fly: Pre-market Movers

HIGHER: Sprouts Farmers Market (SFM), up 6% after Bloomberg reporting that Cerberus Capital-backed Albertsons has held preliminary merger talks with the company. Shares of larger competitor Whole Foods Market (WFM) are also up 2% following the report of industry consolidation conversations... Nektar Therapeutics (NKTR), up 22% after announcing that a Phase 3 efficacy study of NKTR-181, a first-in-class opioid analgesic that the FDA has granted Fast Track designation for the treatment of moderate to severe chronic pain, met the primary efficacy endpoint of the study and key secondary endpoints... CytomX Therapeutics (CTMX), up 34% after announcing an expansion of the company's strategic collaboration with Bristol-Myers Squibb (BMY)... Esperion Therapeutics (ESPR), up 30% after announcing the FDA recently confirmed that Esperion's LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid... Eli Lilly (LLY), up 1% after the company announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival. The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy. Oclaro (OCLR), up 2% after announcing that it has been selected by Ciena (CIEN) as a long-term partner in the development of 400G coherent networks. DOWN AFTER EARNINGS: Movado (MOV), down 7%. LOWER: Aevi Genomic Medicine (GNMX), down 60% after announcing that its SAGA trial of AEVI-001 in adolescents with mGluR mutation positive, or mGluR+, ADHD did not meet the primary endpoint of reduction on the ADHD rating scale compared to placebo... Array BioPharma (ARRY), down 11% after the company withdrew its FDA application for binimetinib in a rare subset of skin cancer.

SFM

Sprouts Farmers Market

$22.02

1.14 (5.46%)

WFM

Whole Foods

$29.53

0.06 (0.20%)

MOV

Movado

LLY

Eli Lilly

BMY

Bristol-Myers

CTMX

CytomX Therapeutics

$15.18

0.18 (1.20%)

NKTR

Nektar

$15.50

-0.21 (-1.34%)

GNMX

Aevi Genomics Medicine

$5.44

-0.12 (-2.16%)

ARRY

Array BioPharma

$10.56

-0.18 (-1.68%)

OCLR

Oclaro

$9.56

0.38 (4.14%)

CIEN

Ciena

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 22

    Mar

  • 23

    Mar

  • 28

    Mar

  • 29

    Mar

  • 01

    Apr

  • 19

    Apr

  • 27

    Apr

  • 09

    May

  • 30

    May

  • 20

    Jun

  • 30

    Jun

SFM Sprouts Farmers Market
$22.02

1.14 (5.46%)

03/20/17
JEFF
03/20/17
NO CHANGE
Target $22
JEFF
Buy
Jefferies sees $26/share buyout price for Sprouts Farmers Market
After Bloomberg reported that Cerberus Capital Management-backed Albertsons held preliminary talks to merge with Sprouts Farmers Market, Jefferies analyst Christopher Mandeville says historical transactions suggest a $26 per share takeout price for Sprouts. The stock in pre-market trading is up 5%, or $1.13, to $23.15. If Sprouts is willing to sell itself, multiple suitors, both financial and strategic, could show interest, leading to a competitive bidding process that could potentially push the valuation higher than $26 per share, Mandeville tells investors in a research note. The company, as one of the last few growth concepts remaining in grocery, should "receive a very healthy valuation," the analyst argues. He has a Buy rating on Sprouts with a $22 price target.
02/02/17
FBCO
02/02/17
NO CHANGE
Target $23
FBCO
Outperform
Re-inflation to alleviate Sprouts Farmers Markets pressure, says Credit Suisse
Credit Suisse analyst Edward Kelly says that while short-term caution is certainly warranted given accelerating produce deflation and a tough overall competitive environment, he thinks Sprouts Farmers Markets' Q4 will eventually result in an attractive opportunity. The analyst believes the stock may be the most leveraged to re-inflation at this point, as comps should see relief when pricing firms, margin pressure should moderate as industry promotions begin to ease, and the valuation has upside given it is likely to remain a growth story. He reiterates an Outperform rating and $23 price target on the shares.
02/27/17
RBCM
02/27/17
NO CHANGE
RBCM
Sprouts Farmers Markets fiscal 2017 guidance conservative, says RBC Capital
After Sprouts reported stronger than expected results, RBC Capital analyst William Kirk says that the company's fundamentals continue to be strong. He thinks that the company's guidance is "beatable," partly due to easing comps and lessening cannibalization, along with the contribution of the company's new stores to comp increases. Kirk remains upbeat on the company's fundamentals and keeps an Outperform rating on the shares.
02/01/17
OTRG
02/01/17
UPGRADE
OTRG
Mixed
Sprouts Farmers Markets upgraded to Mixed from Negative at OTR Global
OTR Global changed its view on Sprouts Farmers Markets to Mixed following checks that indicate orders improved slightly in Q4 due to promotions.
WFM Whole Foods
$29.53

0.06 (0.20%)

02/02/17
CLVD
02/02/17
NO CHANGE
CLVD
Whole Foods estimate lowered on softenting trends at Cleveland Research
02/09/17
FBCO
02/09/17
NO CHANGE
Target $36
FBCO
Outperform
Whole Foods price target lowered to $36 from $40 at Credit Suisse
Credit Suisse analyst Edward Kelly lowered his price target for Whole Foods to $36 from $40 following the company's mixed Q1 earnings update. The analyst reiterates an Outperform rating on the shares as he continues to see value in the brand, believes there is a path for improved performance over time, and likes the stock's risk/reward.
02/09/17
PIVT
02/09/17
NO CHANGE
Target $20
PIVT
Sell
Pivotal calls Whole Foods sales deceleration 'alarming'
Pivotal Research analyst Ajay Jain believes Whole Foods' sales are decelerating at an "alarming rate." The company's guidance reduction last night is the latest in a multi-year string of earnings setbacks, Jain tells investors in a post-earnings research note. He keeps a Sell rating on the shares with a $20 price target.
01/20/17
01/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Aegis. 2. Alphabet (GOOG, GOOGL) and Facebook (FB) were resumed with an Overweight at Pacific Crest, while Twitter (TWTR) was resumed with a Sector Weight. 3. Costco (COST) coverage was resumed with a Buy at Stifel, while Wal-Mart (WMT) and Target (TGT) were resumed with a Hold. 4. Whole Foods (WFM) was initiated with a Market Perform, while Sprouts Farmers Markets (SFM) was initiated with an Outperform at William Blair. 5. CBS (CBS) was reinstated with an Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MOV Movado

11/22/16
SIDC
11/22/16
NO CHANGE
Target $34
SIDC
Buy
Movado price target raised to $34 from $29 at Sidoti
Sidoti analyst Frank Camma raised his price target for Movado to $34 from $29 on "solid" Q3 earnings, newly introduced 2018 estimates and the announcement of a new licensed fashion brand. The analyst is impressed by the company's ability to produce a "solid" gross margin in light of a tepid retail landscape and pressures to discount prices. Additionally, Camma sees the signing of the Rebecca Minkoff fashion brand as an incremental approach to gain traction with millennial consumers. He reiterates a Buy rating on the shares.
01/30/17
01/30/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) and Madison Square Garden (MSG) were upgraded to Overweight from Equal Weight at Morgan Stanley. 2. Dick's Sporting (DKS) upgraded to Buy from Neutral at Goldman with analyst Stephen Tanal saying he believes Dick's is well positioned in a post The Sports Authority world and will reap the rewards of consolidation through sales and earnings growth driven by share gains and improved product allocations from key vendors. Further, Dick's is transitioning to a fully in-sourced eCommerce operation, which should drive improved profitability. 3. American Express (AXP) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Sanjay Sakhrani citing improved fundamentals and visibility. "The low end of the company's 2017 earnings guidance is 'very achievable' just through stated operating cost reductions and capital management, and any revenue growth represents upside potential," Sakhrani tells investors in a research note. He raised his price target for American Express shares to $91 from $81. 4. Royal Caribbean (RCL) upgraded to Buy from Hold at Argus with analyst John Staszak says the company has "few competitors and strong market opportunities." He expects it to benefit from lower costs and increased international demand going forward. 5. Movado (MOV) upgraded to Buy from Neutral at Sidoti with analyst Frank Camma saying recent retail weakness is reflected in price and tariff concerns are overblown. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/30/17
SIDC
01/30/17
UPGRADE
SIDC
Buy
Movado upgraded to Buy from Neutral at Sidoti
Sidoti analyst Frank Camma upgraded Movado to Buy and maintained its $34 price target saying recent retail weakness is reflected in price and tariff concerns are overblown.
12/15/16
SIDC
12/15/16
DOWNGRADE
Target $34
SIDC
Neutral
Movado downgraded to Neutral from Buy at Sidoti
Sidoti analyst Frank Camma downgraded Movado Group to Neutral citing valuation and the "tepid" retail environment. The analyst keeps a $34 price target for the shares.
LLY Eli Lilly

01/19/17
SBSH
01/19/17
NO CHANGE
Target $100
SBSH
Buy
Eli Lilly story 'sharper' after solanezemab failure, says Citi
Citi analyst Andrew Baum believes Eli Lilly's (LLY) equity story has "become sharper" with the uncertainty of the failed solanezemab trial now removed. Recent and anticipated launches are set to drive an anticipated annual earnings growth rate of 13% over the next five years, Baum tells investors in a research note. He views the growth as attractive and continues to prefer Lilly and Bristol-Myers (BMY) among the U.S. major pharmaceutical names. The analyst lowered his price target for Lilly shares to $100 from $110 to reflect the failure in Alzheimer's and keeps a Buy rating on the name.
03/20/17
UBSW
03/20/17
NO CHANGE
Target $85
UBSW
Neutral
Eli Lilly price target raised to $85 from $70 at UBS
UBS analyst Marc Goodman raised his price target on Eli Lilly to $85 from $70 as he updated his model to account for two months of IMS prescription data. Overall his 2017 revenues are largely unchanged but he raised his estimates slightly for 2018. Goodman also noted the positive upcoming data readouts are likely priced into the stock already. Goodman maintained a Neutral rating on Eli Lilly shares.
01/23/17
LEHM
01/23/17
DOWNGRADE
Target $45
LEHM
Equal Weight
CoLucid Pharmaceuticals downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Douglas Tsao downgraded CoLucid Pharmaceuticals (CLCD) to Equal Weight citing the takeover agreement by Eli Lilly (LLY). The analyst keeps a $45 price target for the shares.
03/16/17
03/16/17
DOWNGRADE

Eli Lilly delines 2%, or $1.36, to $84.52
BMY Bristol-Myers

02/15/17
DBAB
02/15/17
NO CHANGE
DBAB
Deutsche not seeing Pfizer buying Bristol-Myers at this time
Following yesterday's speculation of a potential deal, Deutsche Bank analyst Gregg Gilbert said he would be surprised to see Pfizer (PFE) make a move on Bristol-Myers Squibb (BMY) at this stage. Such an acquisition "would represent a very large and concentrated opportunity/risk on immuno-oncology, an area fraught with near-term uncertainty," Gilbert told investors last night in a research note. He believes that if Pfizer were to use $90B for a deal, it would prefer to acquire a more diverse set of value drivers. The analyst keeps a Hold rating on Bristol and Buy rating on Pfizer. Bristol shares rose 3% yesterday to $53.71 amid speculation of a potential takeover. The conjecture had Roche (RHHBY), Novartis (NVS) and Pfizer potentially looking into a bid for Bristol.
02/01/17
GSCO
02/01/17
NO CHANGE
GSCO
Bristol-Myers estimates trimmed for Sprycel loss at Goldman
Goldman reduced Bristol-Myers earnings estimates by 4c-7c for 2017-2021 to reflect the lost of the Sprycel appeal in the EU. The firm continues to rate Bristol-Myers a Buy.
03/06/17
FBCO
03/06/17
NO CHANGE
FBCO
Near-Term acquisition of Bristol-Myers unlikely, says Credit Suisse
Credit Suisse analyst Vamil Divan says there is increasing investor focus on strategic actions and opportunities around Bristol-Myers (BMY) following the company's recent stumbles and the increased stake activist investors have taken in the stock. The analyst notes that "the big question" remains whether any of its peers may be interested in an outright acquisition, with Pfizer (PFE), Novartis (NVS) and Gilead (GILD) among the possible acquirers. While the numbers may make sense, Divan sees an acquisition in the next 9-12 months as unlikely as he needs more clarity on some of the large unknowns in the lung cancer market and macro issues such as corporate tax reform.
03/08/17
PIPR
03/08/17
NO CHANGE
Target $60
PIPR
Neutral
Piper views near-term takeout of Bristol-Myers as unlikely
In a research note titled "Lung Data to Define Value....Not M&A Talk," Piper Jaffray analyst Richard Purkiss contends that news reports suggesting Bristol-Myers (BMY) is a takeover target are "wide of the mark." Industry buyers are unlikely to show interest ahead of the immuno-oncology data readouts in the next 12 months, Purkiss tells investors. He believes the key value-defining events for Bristol over the next year are the four large I/O Combo studies set to read out from mid-2017: AstraZeneca's (AZN) MYSTIC, Merck's (MRK) KN-189, Roche's (RHHBY) IMpower 150 and the company's own CheckMate-227. Ahead of these data, it is virtually impossible to assign a stable fair value to Bristol's I/O franchise, Purkiss argues. He believes investors seeking to benefit from industry consolidation in the near-term should own small- or mid-cap oncology companies. The analyst has a Neutral rating on Bristol with a $60 price target. The stock closed yesterday down 64c to $56.33.
CTMX CytomX Therapeutics
$15.18

0.18 (1.20%)

03/01/17
NOMU
03/01/17
INITIATION
Target $21
NOMU
Buy
CytomX Therapeutics initiated with a Buy at Nomura
Nomura initiated CytomX Therapeutics with a Buy and a $21 price target.
01/03/17
OPCO
01/03/17
DOWNGRADE
OPCO
Perform
CytomX Therapeutics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann downgraded CytomX Therapeutics to Perform citing valuation. The analyst's model assumes only one of the company's experimental therapies has a revenue impact between 2016 and 2025.
NKTR Nektar
$15.50

-0.21 (-1.34%)

12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
01/26/17
PIPR
01/26/17
NO CHANGE
PIPR
Overweight
Celgene acquisition highlights underappreciated Nektar asset, says Piper Jaffray
After Celgene (CELG) announced this morning a deal to acquire Delinia for $300M plus up to $475M in potential milestones, Piper Jaffray analyst Joshua Schimmer noted that the company's lead asset, DEL106, being developed for autoimmune disorders, is similar to Nektar's (NKTR) NKTR-358. While many investors are familiar with Nektar's immune-oncology program, NKTR-214, far fewer are familiar with NKTR-358, though both represent potential blockbuster opportunities if successful, Schimmer tells investors. He keeps an Overweight rating on Nektar, which he identifies as one of his top mid-cap picks.
01/06/17
BTIG
01/06/17
INITIATION
Target $22
BTIG
Buy
Nektar initiated with a Buy at BTIG
BTIG analyst Robert Hazlett started Nektar Therapeutics with a Buy rating and $22 price target. Several "intriguing" emerging therapeutics along with multiple near-term catalysts make the shares attractive, Hazlett tells investors in a research note.
01/03/17
JANY
01/03/17
NO CHANGE
JANY
Janney sees pricing, rising rates as biotech headwinds in 2017
Janney Capital analyst Debjit Chattopadhyay noted that, on a relative basis vs. the Nasdaq, 2016 was the worst year for the Nasdaq biotechnology index (NBI) since 1994 and he believes the "outlook for 2017 isn't particularly rosy" given structural challenges for the sector along with rising interest rates. He cautions about overenthusiasm on M&A, as Chattopadhyay thinks "cash rich pharma may choose to return cash to shareholders through increased buybacks and dividends," and he believes "M&A, if any, is likely to lead to short-term relief rallies and may not represent a broader turn in sentiment." Meanwhile, broader discussion on healthcare spending and regulatory changes are likely to be bigger drivers of biotech sentiment during 2017 than M&A, said Chattopadhyay, who listed bluebird bio (BLUE), Galapagos NV (GLPG), Vertex (VRTX), Clovis (CLVS) and Nektar (NKTR) as on the firm's 2017 biotechnology focus list.
GNMX Aevi Genomics Medicine
$5.44

-0.12 (-2.16%)

01/05/17
JEFF
01/05/17
NO CHANGE
JEFF
Celgene, Alkermes among Jefferies' top 2017 Biotech picks
Jefferies' Biotechnology equity research team laid out their top picks for 2017. Following a volatile two years, the biotech space seeks to achieve "greater equilibrium" in 2017, the analysts write in a research note. They cite increasing competition, slowing volumes, and ramping payer leverage as reasons to remain selective when picking stocks this year and beyond. Among large-caps, Jefferies likes Celgene (CELG) for its "best-in-class growth" and sees limited downside in Gilead (GILD) shares. In the mid-cap space, the firm favors Alkermes (ALKS) given the prospects for Vivitrol and Aristada and a "strong" neurology pipeline as well as Vertex (VRTX). Jefferies' top small-cap picks include Aevi Genomics Medicine, Alder Biopharmaceuticals (ALDR), AMAG Pharmaceuticals (AMAG), DBV Technologies (DBVT), Immunomedics (IMMU), Ignyta (RXDX), Karyopharm (KPTI), RA Pharmaceuticals (RARX), TherapeuticsMD (TXMD) and Xenon Pharmaceuticals (XENE).
02/22/17
JMPS
02/22/17
INITIATION
JMPS
Outperform
Aevi Genomics Medicine coverage assumed with an Outperform at JMP Securities
JMP Securities analyst Jason Butler assumed coverage of Aevi Genomics Medicine with an $8 price target and an Outperform rating.
ARRY Array BioPharma
$10.56

-0.18 (-1.68%)

03/20/17
JPMS
03/20/17
NO CHANGE
Target $9
JPMS
Neutral
JPMorgan sees Array down 5%-10% on withdrawal news
JPMorgan analyst Anupam Rama says Array BioPharma's withdrawal of its new drug application filing for binimetinib in NRAS melanoma is a surprise. The analyst lowered his price target for the shares to $9 from $10 and thinks the stock today could be down 5%-10%. The analyst notes that NRAS melanoma only contributed around $100M in peak sales and $1 per share to his model. Rama keeps a Neutral rating on Array. The stock in premarket trading is down 14%, or $1.41, to $9.15.
03/20/17
LEER
03/20/17
NO CHANGE
Target $9
LEER
Market Perform
Binimetinib NDA withdrawal 'a clear setback' for Array BioPharma, says Leerink
Leerink analyst Michael Schmidt notes that Array BioPharma announced it has withdrawn its new drug application for binimetinib in NRAS+ melanoma following recent FDA interactions since results of the Phase 3 trial do not support regulatory approval. While NRAS+ melanoma was only a small value driver for the company, the analyst thinks this comes as a surprise to investors and is "a clear setback" for Array and management's regulatory and commercial strategy. He reiterated a Market Perform rating on the stock, and lowered his price target on the shares to $9 from $11.
03/20/17
COWN
03/20/17
NO CHANGE
Target $14
COWN
Outperform
Array BioPharma weakness a buying opportunity, says Cowen
Cowen analyst Chris Shibutani said Array's decision to withdraw its application for binimetinib monotherapy for the treatment of NRAS-mutant melanoma was prudent given the known modest efficacy benefit. He views the decision as a de-risking event and said weakness in the shares is a buying opportunity. Shibutani reiterated his Outperform rating and lowered his price target to $14 from $15 on Array Biopharma shares.
03/20/17
WELS
03/20/17
NO CHANGE
WELS
Array chances in BRAF not impacted by NRAS melanoma withdrawal, says Wells Fargo
After Array BioPharma withdrew its application for FDA approval of its binimetinib drug as an NRAS mutant melanoma treatment following a meeting with the agency, Wells Fargo does not think the withdrawal impacts the chances of the drug succeeding as a treatment for BRAF melanoma. Wells says that the BRAF indication is larger, while the benefit of the drug is also greater in that indication and it appears to be best in class. Wells trimmed its price target on Array to $13-$15 from $16-$18 but keeps an Outperform rating on the shares.
OCLR Oclaro
$9.56

0.38 (4.14%)

03/08/17
CHLM
03/08/17
NO CHANGE
CHLM
Buy
ZTE settlement removes overhang on Oclaro shares, says Craig-Hallum
Craig-Hallum analyst Richard Shannon notes that Oclaro (OCLR) top customer ZTE (ZTCOY) has settled with the U.S. and has agreed to a $1.2B fine. The analyst believes this eliminates the overhang on Oclaro's stock that has been there for the past year. The remaining issue with most investors is potential China inventory, which he believes is overblown. Shannon reiterates a Buy rating on Oclaro's shares.
03/03/17
CHLM
03/03/17
NO CHANGE
CHLM
Buy
Oclaro should be bought on potential ZTE settlement, says Craig-Hallum
Craig-Hallum analyst Richard Shannon believes Oclaro should be bought as news emerges that ZTE may settle with the U.S. Department of Commerce and permanently remove restrictions. The analyst says Oclaro's stock has been affected by ZTE as well as fears about a slowdown in China, which are overblown for the company. He reiterates a Buy rating on the shares.
03/15/17
CHLM
03/15/17
NO CHANGE
CHLM
Buy
Oclaro a 'great buying opportunity,' says Craig-Hallum
Craig-Hallum analyst Richard Shannon believes Oclaro (OCLR) is a "great buying opportunity" at current prices. The analyst says concerns about China inventory are unfounded as there does not appear to be any ZTE (ZTCOY)-related issues, while NeoPhotonics (NPTN) dynamics are distinctly different than Oclaro's. Shannon notes that the latter's stock is "easily the cheapest" in the optical universe, suggesting very low downside risk and making it his best idea in the space. He reiterates a Buy rating on Oclaro's shares.
03/16/17
BNCH
03/16/17
NO CHANGE
Target $40
BNCH
Buy
II-VI selloff a buying opportunity, says Benchmark
Benchmark analyst Mark Miller noted that a recent selloff in several optical telecom equipment stocks - including II-VI (IIVI), Lumentum (LITE), and Oclaro (OCLR) - has followed the disappointing earnings and guidance issued by Finisar (FNSR). Additionally weighing on II-VI was technical selling after its stock fell below its 50-day moving average, Miller tells investors. He said he views the selloff in II-VI as a buying opportunity and keeps a Buy rating and $40 price target on the shares.
CIEN Ciena

03/16/17
GSCO
03/16/17
DOWNGRADE
Target $27
GSCO
Neutral
Ciena downgraded to Neutral from Conviction Buy at Goldman
Goldman Sachs analyst Doug Clark downgraded Ciena to Neutral citing rising competition and his expectations for limited margin upside going forward. The analyst keeps a $27 price target for the shares.
03/09/17
NEED
03/09/17
NO CHANGE
Target $30
NEED
Buy
Needham remains a buyer of Ciena despite 'light results'
Needham analyst Alex Henderson says that while Ciena missed forecasts and offered a bit light guide, demand was robust, even a bit stronger than expected, and the pipeline accelerated despite the normal seasonal weakness of the January quarter. The miss was all in Service Revenues, which should snap back to trend line while Products and Software sales came in ahead of forecast, he points out. Henderson remains a buyer of the shares, reiterating a Buy rating and $30 price target on the stock.
03/09/17
BMOC
03/09/17
NO CHANGE
BMOC
Ciena should be bought on weakness, says BMO Capital
BMO Capital analyst Tim Long says that Ciena's weakness following its results was overdone. The analyst says that the company's demand metrics were "strong," while "2017 is shaping up largely as expected." Long continues to "view Ciena as a clear winner in the optical space," and he keeps a $30 price target and an Outperform rating on the stock.
03/09/17
COWN
03/09/17
NO CHANGE
Target $35
COWN
Outperform
Ciena weakness a buying opportunity, says Cowen
Cowen analyst Paul Silverstein noted Ciena reported disappointing Q2 operating results but he also saw some positives in the report. Silverstein said the results offered support for a long-term positive view with improving visibility, increasing revenue diversification, and strong trends in its key product markets. Silverstein reiterated his Outperform rating and $35 price target on Ciena shares and views weakness after earnings as a buying opportunity.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$910.67

-0.31 (-0.03%)

, GOOGL

Alphabet Class A

$926.18

-1.48 (-0.16%)

16:32
08/19/17
08/19
16:32
08/19/17
16:32
Periodicals
Google working on new tools to boost news subscriptions, WSJ reports »

Google is said to be…

GOOG

Alphabet

$910.67

-0.31 (-0.03%)

GOOGL

Alphabet Class A

$926.18

-1.48 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

SRE

Sempra Energy

$116.55

0.76 (0.66%)

, BRK.A

Berkshire Hathaway

$267,377.00

302 (0.11%)

16:27
08/19/17
08/19
16:27
08/19/17
16:27
Periodicals
Sempra Energy is third bidder for Oncor Electric, Bloomberg reports »

Sempra Energy (SRE) is…

SRE

Sempra Energy

$116.55

0.76 (0.66%)

BRK.A

Berkshire Hathaway

$267,377.00

302 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

16:20
08/19/17
08/19
16:20
08/19/17
16:20
Periodicals
Advance Auto Parts hit wall on Q2 results, but turnaround intact, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$34.38

-13.32 (-27.92%)

, AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

16:13
08/19/17
08/19
16:13
08/19/17
16:13
Periodicals
Retail stocks swings could provide opportunity, Barron's says »

This earnings season,…

FL

Foot Locker

$34.38

-13.32 (-27.92%)

AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

LB

L Brands

$36.20

-1.35 (-3.60%)

URBN

Urban Outfitters

$19.27

0.33 (1.74%)

ROST

Ross Stores

$59.02

5.69 (10.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$32.67

-0.28 (-0.85%)

, BMY

Bristol-Myers

$56.42

-0.35 (-0.62%)

16:05
08/19/17
08/19
16:05
08/19/17
16:05
Periodicals
Pharmaceutical companies not the only ones with healthy dividends, Barron's says »

Most income investors are…

PFE

Pfizer

$32.67

-0.28 (-0.85%)

BMY

Bristol-Myers

$56.42

-0.35 (-0.62%)

CAH

Cardinal Health

$64.38

-0.78 (-1.20%)

PDCO

Patterson Companies

$36.45

-0.31 (-0.84%)

RMD

ResMed

$73.07

0.28 (0.38%)

ABC

AmerisourceBergen

$78.60

-1.34 (-1.68%)

UNH

UnitedHealth

$190.82

-1.88 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 27

    Aug

  • 28

    Aug

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

  • 11

    Sep

  • 11

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 21

    Sep

  • 24

    Sep

  • 09

    Nov

  • 05

    Mar

GDI

Gardner Denver

$21.97

-0.03 (-0.14%)

, KKR

KKR

$18.14

0.11 (0.61%)

15:54
08/19/17
08/19
15:54
08/19/17
15:54
Periodicals
Gardner Denver integrated strategy beginning to pay off, Barron's says »

Under KKR (KKR), who…

GDI

Gardner Denver

$21.97

-0.03 (-0.14%)

KKR

KKR

$18.14

0.11 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$87.37

0.24 (0.28%)

, T

AT&T

$37.37

-0.23 (-0.61%)

15:47
08/19/17
08/19
15:47
08/19/17
15:47
Periodicals
Public-safety broadband network may supplant Motorola systems, Barron's says »

FirstNet has tapped…

MSI

Motorola Solutions

$87.37

0.24 (0.28%)

T

AT&T

$37.37

-0.23 (-0.61%)

CCI

Crown Castle

$104.12

-0.02 (-0.02%)

SBAC

SBA Communications

$142.90

0.69 (0.49%)

AMT

American Tower

$140.00

0.35 (0.25%)

COMM

CommScope

$33.00

0.16 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

LMT

Lockheed Martin

$299.20

-2.22 (-0.74%)

15:39
08/19/17
08/19
15:39
08/19/17
15:39
Periodicals
Lockheed Martin should benefit from boost in military outlays, Barron's says »

Large-cap defense stocks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

SBUX

Starbucks

$52.70

-0.34 (-0.64%)

15:26
08/19/17
08/19
15:26
08/19/17
15:26
Periodicals
Starbucks could jump 20%, Barron's says »

There were plenty of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 02

    Nov

  • 25

    Jan

MRK

Merck

$61.49

-0.35 (-0.57%)

, INTC

Intel

$35.01

-0.16 (-0.45%)

15:05
08/19/17
08/19
15:05
08/19/17
15:05
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

MRK

Merck

$61.49

-0.35 (-0.57%)

INTC

Intel

$35.01

-0.16 (-0.45%)

UA

Under Armour

$15.64

-0.64 (-3.93%)

UAA

Under Armour

$17.12

-0.69 (-3.87%)

CPB

Campbell Soup

$53.69

-0.27 (-0.50%)

JNJ

Johnson & Johnson

$132.63

-0.41 (-0.31%)

UTX

United Technologies

$115.48

-0.62 (-0.53%)

BX

Blackstone

$31.52

-0.08 (-0.25%)

JPM

JPMorgan

$90.74

0.09 (0.10%)

GM

General Motors

$34.83

-0.17 (-0.49%)

WMT

Wal-Mart

$79.31

-0.39 (-0.49%)

TSLA

Tesla

$347.46

-4.46 (-1.27%)

DIS

Disney

$100.70

-0.68 (-0.67%)

AMZN

Amazon.com

$958.47

-2.1 (-0.22%)

AET

Aetna

$154.45

-1.36 (-0.87%)

ANTM

Anthem

$191.02

-0.94 (-0.49%)

CNC

Centene

$83.49

-0.13 (-0.16%)

CI

Cigna

$177.03

-1 (-0.56%)

HNT

Health Net

HUM

Humana

$247.28

-0.38 (-0.15%)

MOH

Molina Healthcare

$59.63

0.12 (0.20%)

UNH

UnitedHealth

$190.82

-1.88 (-0.98%)

WCG

WellCare

$173.56

-2.2 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 24

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 31

    Aug

  • 05

    Sep

  • 06

    Sep

  • 07

    Sep

  • 08

    Sep

  • 11

    Sep

  • 12

    Sep

  • 22

    Sep

  • 22

    Sep

  • 26

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 12

    Oct

  • 08

    Nov

  • 16

    Nov

  • 20

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

CTL

CenturyLink

$19.16

-0.22 (-1.14%)

, LVLT

Level 3

$52.69

-0.3 (-0.57%)

14:52
08/19/17
08/19
14:52
08/19/17
14:52
Hot Stocks
CenturyLink continues to expect acquisition of Level 3 to be complete by Q3 »

CenturyLink (CTL) said in…

CTL

CenturyLink

$19.16

-0.22 (-1.14%)

LVLT

Level 3

$52.69

-0.3 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$105.80

-0.07 (-0.07%)

17:45
08/18/17
08/18
17:45
08/18/17
17:45
Hot Stocks
Kansas City Southern director Henry Maier buys 3,000 shares »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RXII

RXi Pharmaceuticals

$0.58

-0.02 (-3.36%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on RXi Pharmaceuticals »

RXi Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WIN

Windstream

$1.98

0.06 (3.13%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Hot Stocks
Windstream CEO acquires 25,381 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$2.44

-0.22 (-8.27%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.20

-0.03 (-0.11%)

17:25
08/18/17
08/18
17:25
08/18/17
17:25
Hot Stocks
ValueAct raises stake inTrinity Industries to 11% from 9.8% »

As of this date, ValueAct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTN

Lpath

17:11
08/18/17
08/18
17:11
08/18/17
17:11
Hot Stocks
Breaking Hot Stocks news story on Lpath »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$48.63

0.12 (0.25%)

17:08
08/18/17
08/18
17:08
08/18/17
17:08
Hot Stocks
Progressive CFO sells 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$172.57

-0.32 (-0.19%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Thermo Fisher director sells 11,318 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SMBC

Southern Missouri Bancorp

$31.18

-0.05 (-0.16%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Southern Missouri Bancorp and Southern Missouri Bancshares to merge »

Southern Missouri Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:58
08/18/17
08/18
16:58
08/18/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ended advisory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says never had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:56
08/18/17
08/18
16:56
08/18/17
16:56
Hot Stocks
Icahn no longer special advisor to President Trump on regulatory reform issues »

Carl Icahn, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:55
08/18/17
08/18
16:55
08/18/17
16:55
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.